¿ Adolor Corp., of Malvern, Pa., signed a development and license agreement with Santen Pharmaceutical Co. Ltd., of Osaka, Japan, for the development and worldwide marketing rights for the topical uses of ADL 2-1294 (lopermide) for the treatment of ophthalmic pain. Adolor will receive an up-front payment and may receive development milestone payments and royalties on net sales.

¿ Allos Therapeutics Inc., of Denver, said preliminary survival results of two Phase II trials of RSR13 combined with cranial radiation therapy in patients with primary brain cancer and patients with brain metastases will be presented at the meeting of the American Society of Clinical Oncology held May 20-23 in New Orleans.

¿ Atrix Laboratories Inc., of Fort Collins, Colo., submitted an investigational new drug application for clinical trials using dapsone topical gel for the treatment of chronic itch associated with healed and healing burn wounds. In addition, it has started Phase II trials of dapsone topical gel for the treatment of moderate to severe acne.

¿ Celera Genomics, of Rockville, Md., said Celera AgGen, its agriculture business, signed an agreement with ViaLactia Biosciences New Zealand Ltd. to discover novel bovine genes that are important for increasing dairy productivity. The companies said the use of genomics to identify important genes and traits at the molecular level will contribute to sustainable improvements in the dairy industry. Celera will use its high-throughput DNA sequencing, library development and advanced bioinformatics capabilities to identify important expressed genes in dairy cattle. All intellectual property will be jointly owned.

¿ Cephalon Inc., of West Chester, Pa., and Medtronic Inc., of Minneapolis, agreed to co-promote Medtronic intrathecal baclofen (ITB) therapy to treat severe spasticity to neurologists and neurosurgeons in the UK, France and Austria. ITB therapy has been shown to significantly reduce severe spasticity (excessive muscle tension) associated with cerebral palsy, traumatic brain injury, spinal cord injury and multiple sclerosis. The agreement is for one year and will be renewed unless terminated by either party.

¿ Cyanotech Corp., of Kailua-Kona, Hawaii, completed a $3.5 million debt transaction with a commercial lender to refinance its existing credit facility and provide working capital. The new loan is a 10-year term loan at an interest rate of prime plus 1 percent. About $1.6 million of the proceeds were used to retire the company's term loan and revolving credit facility, while the balance will be used for working capital.

¿ Immtech International Inc., of Vernon Hills, Ill., said it is establishing a research consortium focused on developing new treatments for leishmaniasis, a parasite-transmitted skin and visceral disease that affects more than 12 million people worldwide. The consortium will include Immtech, The London School of Hygiene and Tropical Medicine in London, as well as Georgia State University. The U.S. Military Research Institute will screen the drug candidates supplied by Georgia State using an in vitro test. Immtech will fund research in London to evaluate the compounds in animal models of the disease.

¿ Neurocrine Biosciences Inc., of San Diego, said its IL-4 Pseudomonas toxin fusion protein (NBI-3001) has been awarded orphan drug status, providing the company with seven years of marketing exclusivity.

¿ Quorum Sciences Inc., of Frederick, Md., said the Cystic Fibrosis Foundation, of Bethesda, Md., awarded nearly $1 million to the company to fund the development of a new antibacterial treatment for the leading cause of chronic lung infections in patients with cystic fibrosis.

¿ Sunesis Pharmaceuticals Inc., of Redwood City, Calif., appointed James Young to the position of CEO, effective May 1. Young comes to Sunesis from Palo Alto, Calif.-based Alza Corp., where he served as group vice president of Alza Technologies.